CD25

Aulos Bioscience to Present Updated Phase 1/2 Clinical Trial Results for Novel IL-2 Therapeutic AU-007 in Advanced Solid Tumor Cancers at 2024 ASCO Annual Meeting

Retrieved on: 
Wednesday, April 24, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Interleukin, CD25, Poster, Artificial intelligence, McCormick Place, ASCO, Immunoglobulin G, Therapy, Patient, Society, Convention, Clinical trial, Annual general meeting, Vaccine

AU-007 is a human IgG1 monoclonal antibody designed using artificial intelligence to harness the power of interleukin-2 (IL-2) to eradicate solid tumors in patients with unresectable locally advanced or metastatic cancers.

Key Points: 
  • AU-007 is a human IgG1 monoclonal antibody designed using artificial intelligence to harness the power of interleukin-2 (IL-2) to eradicate solid tumors in patients with unresectable locally advanced or metastatic cancers.
  • It is the first AI-designed human monoclonal antibody to be tested in a clinical trial.
  • The ASCO meeting is being held online and at McCormick Place in Chicago, Illinois, from May 31–June 4, 2024.
  • An electronic version will also be available on the ASCO 2024 online meeting platform.

Phio Pharmaceuticals Presenting Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies

Retrieved on: 
Thursday, March 21, 2024
ACT, Gene silencing, Metabolism, Conference, Immunotherapy, CD25, CD98, Compound, RNA interference, Bone marrow, Poster, NK, Chronic myelogenous leukemia, Pharmaceutical industry

The data reveals a consistent silencing of Cbl-b mRNA, which has been shown to limit NK cell activation.

Key Points: 
  • The data reveals a consistent silencing of Cbl-b mRNA, which has been shown to limit NK cell activation.
  • These preclinical data demonstrate the potential of INTASYL Compound PH-905 to improve Adoptive Cell Therapy (ACT) by targeting and silencing Cbl-b.
  • This may result in a more effective cell therapy for hematological malignancies.
  • INTASYL compound PH-905 may be used to improve the anti-tumor response of NK cells to provide a more effective cell therapy for cancer treatment.

Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer

Retrieved on: 
Wednesday, February 28, 2024
Therapy, AstraZeneca, CMO, CD25, Biotechnology, Roche, Neoplasm, Physician, Obesity, Amgen, Icon, Pharmaceutical medicine, Bladder cancer, Royal college, ADC, Antibody, NHS, Safety, CB1, CSPC, Patient, CD137, Faculty, Partnership, Pharmaceutical industry

NORWOOD, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today announced the appointment of Dr. Dominic Smethurst, MA MRCP, as the Company’s Chief Medical Officer (CMO).

Key Points: 
  • NORWOOD, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today announced the appointment of Dr. Dominic Smethurst, MA MRCP, as the Company’s Chief Medical Officer (CMO).
  • Additionally, Dr. Smethurst will help guide strategic development of CRB-913, the Company’s highly peripherally restricted CB1 inverse agonist for the treatment of obesity.
  • “We are pleased to welcome Dominic to the Corbus team and look forward to benefitting from his experience in developing novel oncology therapeutics including ones that specifically target Nectin-4", said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus.
  • Previously, Dr. Smethurst worked as a consultant advising biopharma companies, providing guidance on clinical development strategies and licensing projects.

First Patient Dosed in Phase 2 Portion of Aulos Bioscience’s Phase 1/2 Clinical Trial for AU-007, a Computationally Designed IL-2 Antibody for Solid Tumor Cancers

Retrieved on: 
Thursday, January 25, 2024
Oncology, Health, Technology, Clinical Trials, Artificial Intelligence, Pharmaceutical, Biotechnology, NK, Immunoglobulin G, Renal cell carcinoma, Neoplasm, Patient, Kidney, Melanoma, Neck, RCC, CD25, Interleukin, Head, Safety, Eosinophil, Therapy, Clinical trial, Cell, Immune system, Vaccine

AU-007 is a human IgG1 monoclonal antibody designed to harness the power of interleukin-2 (IL-2) to eradicate solid tumors, and the first AI-designed human monoclonal antibody to be tested in a clinical trial.

Key Points: 
  • AU-007 is a human IgG1 monoclonal antibody designed to harness the power of interleukin-2 (IL-2) to eradicate solid tumors, and the first AI-designed human monoclonal antibody to be tested in a clinical trial.
  • Phase 1 data demonstrate that AU-007 is currently the only IL-2 agent that can reduce regulatory T cells (Tregs), which suppress the immune system.
  • This redirects IL-2 to medium-affinity receptors on effector T cells (Teffs) and natural killer (NK) cells, which expand and kill tumor cells.
  • To learn more about the AU-007 clinical trial program, please visit ClinicalTrials.gov (identifier: NCT05267626 ).

New Study Reports IceCure's ProSense® Boosts Immune Response Against Cancer: Enhances CD8+ T Cell Response

Retrieved on: 
Wednesday, January 3, 2024
Freezing, Neoplasm, Cryoablation, Immune system, Research, Immunotherapy, Human, Immunity, Patient, Journal, CD25, Vaccine

The Piezo1 study involved performing cryoablation with ProSense® on tumor volumes of approximately 100 mm3 (diameter ~6 mm) using a mouse model.

Key Points: 
  • The Piezo1 study involved performing cryoablation with ProSense® on tumor volumes of approximately 100 mm3 (diameter ~6 mm) using a mouse model.
  • The data demonstrates that cryoablation induces immune rejection by enhancing CD8+ T cell activation, a process dependent on T cell expression of Piezo1.
  • "These studies pave the way for analysis of immune response in the growing number of ProSense® cryoablation investigator-initiated trials in humans.
  • As always, we are very grateful to the doctors conducting these independent studies that explore and confirm ProSense®'s mechanism of action and its benefits for patients."

Aulos Bioscience Advances AU-007 to Phase 2 Portion of Phase 1/2 Study Evaluating Computationally Designed IL-2 Antibody for Treatment of Solid Tumors

Retrieved on: 
Monday, December 18, 2023
Research, Technology, Clinical Trials, Health Technology, Biotechnology, Pharmaceutical, Health, Science, Oncology, Artificial Intelligence, Renal cell carcinoma, Safety, Annual general meeting, Immunoglobulin G, Karen Teff, Clinical trial, Patient, Regulatory T cell, Kidney, Artificial intelligence, Immunotherapy, Interleukin, Neoplasm, RCC, CD25, Therapy, Melanoma, SITC, Eosinophil, Skin, Cell, NK, Pharmaceutical industry, Vaccine

AU-007 is a human IgG1 monoclonal antibody designed using artificial intelligence to harness the power of interleukin-2 (IL-2) to eradicate solid tumors.

Key Points: 
  • AU-007 is a human IgG1 monoclonal antibody designed using artificial intelligence to harness the power of interleukin-2 (IL-2) to eradicate solid tumors.
  • This is encouraging as the anti-tumor activity has been observed in heavily pre-treated patients whose tumors had progressed through checkpoint inhibitors.
  • Clinical data from the Phase 1/2 study were presented at the 38th Society for Immunotherapy of Cancer (SITC) Annual Meeting in November.
  • Created by Biolojic Design, AU-007 is the first computationally designed monoclonal antibody to be tested in a clinical trial.

New Phase 1 Dose Escalation Data Show Well-Tolerated Safety Profile and Anti-Tumor Activity for Aulos Bioscience’s AU-007 at Society for Immunotherapy of Cancer (SITC) Annual Meeting

Retrieved on: 
Friday, November 3, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Regulatory T cell, Neoplasm, Lymphocytopenia, Society for Immunotherapy of Cancer, NSCLC, Renal cell carcinoma, Therapy, Eosinophil, Kidney, Cell, RCC, Abstract (summary), CD8, Artificial intelligence, SITC, Immunotherapy, Clinical trial, NK, Immunoglobulin G, Annual general meeting, CT, Lung cancer, Melanoma, Safety, Patient, Interleukin, CD25, Karen Teff, Toxic epidermal necrolysis, Pharmaceutical industry, Vaccine

The data also demonstrate early evidence of anti-tumor activity in patients with several solid tumor cancer types.

Key Points: 
  • The data also demonstrate early evidence of anti-tumor activity in patients with several solid tumor cancer types.
  • “These encouraging new data support AU-007’s distinct advantages in the IL-2 class,” said Aron Knickerbocker, Aulos Bioscience’s chief executive officer .
  • At this point, we are observing the greatest anti-tumor activity in patients with tumors known to be sensitive to immune-modulating drugs.
  • These data support our decision to focus our Phase 2 expansion cohorts in melanoma, renal cell carcinoma and non-small cell lung cancer.

New Phase 1 Dose Escalation Cohorts Data for Aulos Bioscience’s AU-007 Show Favorable Pharmacodynamic Effects at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Retrieved on: 
Saturday, October 14, 2023
Research, Technology, Clinical Trials, Health Technology, Biotechnology, Pharmaceutical, Health, Science, Oncology, Artificial Intelligence, Immunoglobulin G, CD25, AACR, Cell, Therapy, Cancer, Toxicity, Safety, Abstract (summary), Eosinophil, Artificial intelligence, Clinical trial, NK, Conference, Patient, Pharmaceutical industry, Vaccine, Regulatory T cell, Karen Teff

The data were shared in a poster presentation at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts.

Key Points: 
  • The data were shared in a poster presentation at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts.
  • The study evaluated AU-007 as a monotherapy treatment or in a combination therapy regimen with low-dose subcutaneous Proleukin® (aldesleukin; recombinant human IL-2).
  • The data also show a reduction in eosinophils, which at high cell counts can be associated with toxicity in the lungs.
  • “These data continue to demonstrate favorable and unique pharmacodynamic effects in the IL-2 class.

Aulos Bioscience to Present Encouraging Pharmacodynamic Data for AU-007 From Phase 1 Dose Escalation Cohorts at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Retrieved on: 
Wednesday, October 4, 2023
Science, Other Science, Biometrics, Research, Oncology, Health, Health Technology, Clinical Trials, Eosinophil, ASCO, CD25, Artificial intelligence, Clinical trial, Poster, AACR, Level 2, Therapy, Toxicity, Patient, Conference, Immune system, Vaccine

The new data will be featured at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, being held October 11-15, 2023, in Boston, Massachusetts.

Key Points: 
  • The new data will be featured at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, being held October 11-15, 2023, in Boston, Massachusetts.
  • “The Phase 1 dose escalation data for our lead candidate, AU-007, builds upon the favorable safety profile data shared during ASCO earlier this year,” said Aron Knickerbocker, Aulos Bioscience’s chief executive officer .
  • “We’re extremely encouraged by these latest data.
  • At the same time, the data demonstrate an overall trend in increasing natural killer cells and effector T cells that can kill tumor cells.

Aulos Bioscience Announces Presentation of Updated Safety and Efficacy Data From First-in-Human Phase 1/2 Clinical Trial of AU-007 at 38th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Retrieved on: 
Wednesday, September 27, 2023
Oncology, Health, Technology, Clinical Trials, Artificial Intelligence, Pharmaceutical, Biotechnology, CD25, San Diego Convention Center, Society, Therapy, SITC, Immunotherapy, Society for Immunotherapy of Cancer, Patient, Immunoglobulin G, Annual general meeting, Mab, Artificial intelligence, Poster, Interleukin, Safety, Pharmaceutical industry

AU-007 is a human IgG1 monoclonal antibody designed using artificial intelligence to harness the power of interleukin-2 (IL-2) to eradicate solid tumors.

Key Points: 
  • AU-007 is a human IgG1 monoclonal antibody designed using artificial intelligence to harness the power of interleukin-2 (IL-2) to eradicate solid tumors.
  • The SITC meeting is being held virtually and in San Diego, California, from November 1-5, 2023.
  • “Using artificial intelligence, AU-007 is designed to bind to IL-2 precisely instead of the IL-2 receptor.
  • It will also be available as an ePoster on display on the SITC 2023 virtual meeting platform.